Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: An effective second-line regimen

Abstract

This regimen is an active second-line therapy in advanced colorectal cancer with minimal toxicity, thus preserving the quality of life during palliative chemotherapy. Antitumor activity in previously untreated patients does not seem superior to that obtained with weekly regimens applying 24- or 48-hour continuous infusions of 5-FU and folinic acid.

A Phase II Study of Modified deGramont 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Treated Patients with Metastatic Colorectal Cancer

“…Streit and colleagues administered infusional 5-FU to 54 patients with advanced colorectal cancer who were previously treated with bolus 5-FU and demonstrated objective responses in 6% of patients and stable disease in 68% of patients. [18] The median survival was 14 months. Similarly, Tralongo and colleagues administered infusional 5-FU to 21 patients who had been previously treated with bolus 5-FU and demonstrated objective responses in 19% of patients and stable disease in 29% of patients.…”

Perspectives on cancer therapy-induced mucosal injury

“…The incidence of oral and GI mucositis varied significantly among different treatment regimens and modalities (Table 4). 60–398 Most anthracycline‐based regimens were associated with rates of oral mucositis in the 1–10% range, except when regimens included 5‐FU. Included among these are the standard regimens for adjuvant therapy in patients with breast cancer (5‐FU, doxorubicin, and cyclophosphamide; doxorubicin and cyclophosphamide; or 5‐FU, epirubicin, and cyclophosphamide) as well as regimens for patients with non‐Hodgkin lymphomas, including cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP).…”

UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors

“…Patients with metastatic colorectal cancer treated with 48-h 5-FU 3.5 g/m 2 by continuous infusion without leucovorin obtained an overall response rate of 38.5% [10], comparable to that reported with different schedules of continuous infusion 5-FU modulated by leucovorin. leucovorin modulation [18]. leucovorin was added to 48-h continuous infusion 5-FU 3-4 g/m 2 [16].…”